Johnson & Johnson at J.P. Morgan Healthcare Conference: January 11-14, 2021

What’s Now and What’s Next

In a year of change, Johnson & Johnson Innovation supported the global innovation ecosystem to adapt and pivot to continue addressing high unmet needs across all areas of health. The company enables and accelerates early scientific discoveries by investing in and partnering with innovators with the potential to positively impact human health.

In January 2021, Johnson & Johnson returned virtually to the 39th Annual J.P. Morgan Healthcare Conference 2021 and J.P. Morgan Week, coming together with industry leaders, emerging innovators and members of the investment community to drive forward potential health solutions.

Deals around the world

Innovation through Collaboration

Accelerating Innovation Worldwide: Company Brochure

A Vision for the Breakthroughs of Tomorrow

During the events on January 11-14, live and on-demand programming sessions featuring Johnson & Johnson leadership took place.

Alex Gorsky, Chairman and Chief Executive Officer and Joseph J. Wolk, Executive Vice President and Chief Financial Officer

J.P. Morgan Healthcare Conference session

Ruxandra Draghia Akli, Global Head, Global Public Health R&D, The Janssen Pharmaceutical Companies of Johnson & Johnson

Biotech Showcase – In conversation with the COVID-19 leaders: In the balance — the humanitarian perspective global policy

Marian Nakada, Vice President, Venture Investments, Johnson & Johnson

Biotech Showcase – Value Creation and Venture

Mathai Mammen, MD, PhD, Global Head of Research and Development at Janssen

2021 CERSI Innovations in Regulatory Science Summit – Advancing Discovery to First-in-Human Clinical Trials for New Medical Products

Susan Morano, Vice President, Business Development, Johnson & Johnson Medical Devices

McDermott & EY – Life Sciences Investment Forum, MedTech

Orlando Serani, Program Architect CAR-T Advanced Cell Therapies Supply Chain, Janssen Pharmaceutical Companies of Johnson & Johnson

McDermott & EY – Life Sciences Investment Forum, Cell and Gene Therapies

Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson

Fierce JPM Week 2021 – “Second-Wave” COVID-19 Vaccines

Stephen Pitt, Ph.D., Head of Johnson & Johnson Innovation – JLABS US North East

Redefining Early Stage Investments – Diagnostics Investors: New Generation of Technologies Changing Treatment Paradigms

Stacy Feld, Head, Johnson & Johnson Innovation, West North America, Australia & New Zealand

Redefining Early Stage Investments – Big Pharma: Pipeline Strategy for Preclinical and Early Clinical Assets policy

Michal Preminger, Ph.D., MBA, Head, Johnson & Johnson Innovation, East North America

WuXi Global Forum – When Technology Meets Healthcare

Sally Allain, Head of JLABS @ Washington DC

Longevity, Health & Innovation – Diagnostics panel, new generation of technologies changing treatment paradigms

Pushing the limits of the ‘speed of science’

Closing over 100 deals in 2020, Johnson & Johnson continued to help global innovators to adapt and thrive in a year of change.

Check out the special JPM 2021 coverage below and hear from our team and our partners on how partnering with Johnson & Johnson can help drive scientific discovery and acceleration.